相似文献
1
Identification and susceptibility of Aspergillus section nigri in china: prevalence of species and paradoxical growth in response to echinocandins.
J Clin Microbiol. 2015 Feb;53(2):702-5. doi: 10.1128/JCM.03233-14. Epub 2014 Dec 10.
2
In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of Aspergillus Nigri Complex.
Mycopathologia. 2016 Apr;181(3-4):235-40. doi: 10.1007/s11046-015-9968-0. Epub 2015 Nov 28.
3
Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp.
Diagn Microbiol Infect Dis. 2012 May;73(1):53-6. doi: 10.1016/j.diagmicrobio.2012.01.006. Epub 2012 Apr 4.
4
Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
Mycopathologia. 2020 Jun;185(3):527-535. doi: 10.1007/s11046-020-00448-7. Epub 2020 Apr 28.
5
In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.
J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26.
6
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
Antimicrob Agents Chemother. 2011 Aug;55(8):3944-6. doi: 10.1128/AAC.00428-11. Epub 2011 Jun 13.
7
Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Mycopathologia. 2016 Apr;181(3-4):225-33. doi: 10.1007/s11046-015-9969-z. Epub 2015 Nov 26.
8
Drug Sensitivity and Resistance Mechanism in Aspergillus Section Strains from Japan.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.02583-16. Print 2017 Aug.
9
Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
Med Mycol. 2009 Mar;47(2):145-8. doi: 10.1080/13693780802262123. Epub 2008 Jul 30.
10
Prospective survey of Aspergillus species isolated from clinical specimens and their antifungal susceptibility: A five-year single-center study in Japan.
J Infect Chemother. 2020 Feb;26(2):321-323. doi: 10.1016/j.jiac.2019.09.002. Epub 2019 Sep 27.
引用本文的文献
1
Otomycosis: a systematic review and meta-analysis of prevalence and causative agents in the era of molecular diagnostics.
BMC Infect Dis. 2025 Apr 17;25(1):544. doi: 10.1186/s12879-025-10954-y.
2
Antifungal Resistance in Non-fumigatus Aspergillus Species.
Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051.
3
Molecular Identification of Species, Antifungal Susceptibility, and Phenotypic Identification of Azole-Resistant Mutations in Cyp51A Gene Isolated from Xinjiang.
Infect Drug Resist. 2025 Apr 2;18:1699-1711. doi: 10.2147/IDR.S496489. eCollection 2025.
4
cyp51A mutations, protein modeling, and efflux pump gene expression reveals multifactorial complexity towards understanding Aspergillus section Nigri azole resistance mechanism.
Sci Rep. 2024 Mar 14;14(1):6156. doi: 10.1038/s41598-024-55237-9.
5
Chitin Biosynthesis in Species.
J Fungi (Basel). 2023 Jan 6;9(1):89. doi: 10.3390/jof9010089.
6
Poly-(lactic--glycolic) Acid Nanoparticles Entrapping Pterostilbene for Targeting Section .
Molecules. 2022 Aug 25;27(17):5424. doi: 10.3390/molecules27175424.
7
Epidemiology, Drug Susceptibility, and Clinical Risk Factors in Patients With Invasive Aspergillosis.
Front Public Health. 2022 Apr 15;10:835092. doi: 10.3389/fpubh.2022.835092. eCollection 2022.
8
Otomycosis in the South of Iran with a High Prevalence of Tympanic Membrane Perforation: A Hospital-Based Study.
Mycopathologia. 2022 Jun;187(2-3):225-233. doi: 10.1007/s11046-022-00626-9. Epub 2022 Mar 26.
9
Aspergillus tubingensis Endocarditis: A Case Report and Review of the Literature.
Mycopathologia. 2022 Jun;187(2-3):249-258. doi: 10.1007/s11046-022-00621-0. Epub 2022 Mar 10.
10
Identification and in vitro antifungal susceptibility of causative agents of onychomycosis due to Aspergillus species in Mashhad, Iran.
Sci Rep. 2021 Mar 24;11(1):6808. doi: 10.1038/s41598-021-86038-z.
本文引用的文献
1
CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP.
Evolution. 1985 Jul;39(4):783-791. doi: 10.1111/j.1558-5646.1985.tb00420.x.
2
MEGA6: Molecular Evolutionary Genetics Analysis version 6.0.
Mol Biol Evol. 2013 Dec;30(12):2725-9. doi: 10.1093/molbev/mst197. Epub 2013 Oct 16.
3
Invasive Aspergillus niger complex infections in a Belgian tertiary care hospital.
Clin Microbiol Infect. 2014 May;20(5):O333-5. doi: 10.1111/1469-0691.12394. Epub 2013 Nov 4.
4
Involvement of the opportunistic pathogen Aspergillus tubingensis in osteomyelitis of the maxillary bone: a case report.
BMC Infect Dis. 2013 Feb 1;13:59. doi: 10.1186/1471-2334-13-59.
5
Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary.
Mycopathologia. 2012 Aug;174(2):143-7. doi: 10.1007/s11046-012-9529-8. Epub 2012 Feb 23.
6
Culture-positive invasive aspergillosis in a medical center in Taiwan, 2000-2009.
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1319-26. doi: 10.1007/s10096-011-1445-1. Epub 2011 Oct 14.
7
Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM/IHEM collection.
Mycoses. 2012 Mar;55(2):148-55. doi: 10.1111/j.1439-0507.2011.02049.x. Epub 2011 Sep 20.
8
Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran.
Mycoses. 2012 Jul;55(4):333-8. doi: 10.1111/j.1439-0507.2011.02103.x. Epub 2011 Sep 7.
9
Cryptic species and azole resistance in the Aspergillus niger complex.
Antimicrob Agents Chemother. 2011 Oct;55(10):4802-9. doi: 10.1128/AAC.00304-11. Epub 2011 Jul 18.
10
Molecular typing and in-vitro activity of azoles against clinical isolates of Aspergillus fumigatus and A. niger in Japan.
J Infect Chemother. 2011 Aug;17(4):483-6. doi: 10.1007/s10156-010-0202-1. Epub 2011 Jan 5.
Zotero 插件